VCBeat (WeChat: vcbeat) has learned that HuiNuo Biopharmaceutical Technology (Hangzhou) Co., Ltd. (hereinafter referred to as “HuiNuo Pharma” or the “Company”) announced the completion of its RMB 100 million Series A+ financing round. The round was led by Boru Capital, with participation from Bori Pharmaceutical and Langyu Capital, among others. Existing investors, including Yuanhe Yuandian, continued to hold their stakes.

The proceeds from this round of financing will be primarily used to accelerate the clinical development of the company’s multiple core products, expand its product pipeline, and advance the R&D of its early-stage projects.

Huinuo Pharmaceuticals was established in Hangzhou in December 2018 as a clinical-stage innovative company dedicated to the research and development of novel anti-infective drugs. The company’s core management team has devoted decades to the study of infectious diseases and possesses extensive experience in international new drug development. Since its inception, Huinuo Pharmaceuticals has focused on developing best-in-class innovative therapeutics for infectious diseases, pursuing a dual strategy of in-licensing and independent R&D, thereby rapidly building a robust pipeline.

Currently, Huinuo Medicine has two Class 1 new drugs in Phase I clinical trials. Among them, the core product HN0141, a novel anti-human cytomegalovirus (HCMV) agent, and HN0037, a novel anti-herpes simplex virus (HSV) agent, are poised to become best-in-class (BIC) therapies. In addition, two other innovative anti-infective drugs led by the company have entered the preclinical development stage and are expected to submit Investigational New Drug (IND) applications for clinical trials within the year.

Dr. Qin Donghui, Founder, Chairman and CEO of Huinuo Pharmaceutical, statedWe sincerely appreciate the trust and recognition from investors such as Borui, Borui Capital, Langyu Capital, and Yuanhe. The market for novel anti-infective drugs in China is vast, with a lack of specific therapeutics in multiple antiviral fields, while bacterial infections—particularly those caused by Gram-negative bacteria—face severe antimicrobial resistance challenges. Within less than three years since its establishment, Huinuo Pharma has achieved rapid growth and strategically positioned itself in highly promising areas of antiviral therapy and treatment of drug-resistant Gram-negative bacterial infections. The company has made significant progress in pipeline development and clinical R&D. This round of financing is crucial for accelerating the advancement of our clinical programs and expanding our product pipeline. We are committed to bringing our products to market as soon as possible to benefit patients in China and around the world.

Ms. Du Hongpin, Founding Partner of Boru Capital, stated: Anti-infective drugs hold significant clinical value both in China and globally. Huinuo Pharma is one of the few domestic companies dedicated to the research and development of novel anti-infective agents. Its robust pipeline, particularly in antiviral and antibacterial therapeutics, has established a leading edge. The founding team has demonstrated global leadership, strategic excellence, and strong execution capabilities. We look forward to Huinuo Pharma, guided by its corporate philosophy of “patient needs first, scientific innovation as the foundation,” to achieve continuous breakthroughs, accelerate the clinical application of its products, and emerge as an internationally leading anti-infective company.

Mr. Zhao Qun of Yuanhe Origin stated: As the lead investor in the previous round, we are delighted to see Huinuo Pharma’s remarkable achievements in the research and development of anti-infective drugs, and we are pleased to continue supporting Huinuo’s growth. It is imperative to establish a specialized company focused on novel anti-infective agents and to develop anti-infective drugs that meet world-class standards. Huinuo Pharma boasts an internationally top-tier background in anti-infective drug R&D and a robust pipeline composed of innovative drugs at the global forefront. We look forward to the company’s continued innovation and breakthroughs in addressing unmet medical needs in the field of infectious diseases, striving to provide safe and accessible new anti-infective therapies for patients in China and around the world.

Huinuo Pharmaceuticals is a clinical-stage innovative company dedicated to the research and development of novel anti-infective drugs. With a leading pipeline of anti-infective products, the company is grounded in China’s pharmaceutical needs and possesses global competitive potential. Its vision is to pioneer new anti-infective therapies and safeguard public health. Huinuo Pharmaceuticals has established a comprehensive team spanning early-stage R&D, drug manufacturing, clinical development, business development, and corporate operations. Founded in Hangzhou, the company has set up an office and a Biosafety Level 2 (BSL-2) laboratory in Shanghai.

WinDigital Capital is a private equity investment fund focused on China, managing several RMB and USD-denominated funds. It is committed to investing in high-quality companies with sound fundamentals and strong growth potential, primarily focusing on the life sciences, artificial intelligence and big data, and new consumer sectors. In the fields of life sciences and medical technology, WinDigital Capital has invested in outstanding enterprises such as ImmuneOnco Biopharmaceuticals, Suzhou Qide Medicine, Beijing Weidejie Pharmaceutical, Huinuo Pharmaceutical, WeDoctor, and Boan Biotech. WinDigital Capital was included in the “Top 10 Most Promising Venture Capital Firms in China for 2020” list published by CVSource.

Laurel Venture Capital is an early-stage innovative pharmaceutical investment firm dedicated to advancing breakthrough life science technologies. We are committed to continuously identifying the most cutting-edge scientific technologies and exceptional partners worldwide to accelerate the global launch of transformative drugs and address unmet clinical needs. With an international team of professionals and scientific advisors, a global perspective, and an extensive resource network, Laurel Venture Capital upholds the principles of integrity, openness, and inclusivity. We look forward to fostering deep collaborations with scientists, research institutions, and startups in the global innovative drug sector.

Yuanhe Origin, a member of Suzhou Yuanhe Holding Co., Ltd., is a professionally managed, market-oriented early-stage equity investment platform. It focuses primarily on investment opportunities in startups and growth-stage enterprises within the Healthcare and TMT sectors. The platform manages ten funds with a total scale of approximately RMB 4 billion, comprising both venture capital (VC) funds and angel funds targeted at specific regions. Yuanhe Origin’s investment style is characterized by a focus on early-stage ventures, a preference for technology-driven companies, and a strong commitment to its promises, earning it a solid reputation among technology-focused early-stage startups. As of December 2020, it had invested in and managed more than 180 high-quality portfolio companies, including Ascentage Pharma, CStone Pharmaceuticals, JW Therapeutics, Beiren Robotics, Tianzhun Technology, Cambricon, Crystal Cloud, Biocytogen, Singleron, Zhizhu, CloudWalk Technology, and Mushroom IoT.